Home
 

neurobid.eu

  • Increase font size
  • Default font size
  • Decrease font size
Home UMC Utrecht
UMC Utrecht



Description

University Medical Center Utrecht (UMC Utrecht) is one of the largest public healthcare institutions in the Netherlands. It offers a unique combination of patient care, biomedical and healthcare research, and the training of doctors, researchers and other healthcare workers. Furthermore, UMC Utrecht is closely affiliated with Utrecht University. Among the Dutch UMCs, UMC Utrecht is second in terms of quantity and first in terms of citation score (1,6). National and international collaboration is an important positive factor in this.


The NEUROBID partners at University Medical Center Utrecht offer comprehensive expertise in neuroimmunology, neonatology and cell biology. This group will contribute two methods to bypass the BBB and to deliver large molecules to the brain: a TAT-coupled peptide approach to transport large molecules over the blood brain barrier and a molecularly engineered mesenchymal stem cell approach.

 

Persons

Cobi Heijnen This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Annemieke Kavelaars This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The group of Cobi Heijnen and Annemieke Kavelaars will offer hypoxia-ischemia models in neonatal mouse and rat and this model will be used to investigate contribution of damage to and restoration of BBB integrity. The group will provide other partners in the consortium with tissues for examination of BBB integrity in the context of hypoxic-ischemic brain damage and repair. They will also contribute a molecularly engineered mesenchymal stem cell approach that this group recently developed to transport large molecules over the BBB.

Frank van Bel This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The neonatology group of Frank van Bel will offer the clinical framework into which the results of the studies performed within NEUROBID will be directly disseminated to this clinical group. Moreover, Frank van Bel will be able to disseminate the results of the project to patient associations and pediatric societies. In addition, this group offers extensive knowledge on neonatal brain damage in humans and is very much interested in the possibility to use the strategies developed within this consortium to pass the BBB and to detect changes in BBB integrity at early phases in the clinic at a later stage.

 

Contact

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Heidelberglaan 100
3508 GA Utrecht
NETHERLANDS

www.umcutrecht.nl

 



Login Form

Who's Online

We have 10 guests online

Funded by the European Commisssion under the grant agreement n° HEALTH-F2-2009-241778.